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Abstract
Background: Reelin plays a pivotal role in neurodevelopment and in post-natal synaptic plasticity and has been
implicated in the pathogenesis of autism spectrum disorder (ASD). The reelin (RELN) gene expression is significantly
decreased in ASD, both in the brain and peripherally. Methylation at the RELN gene promoter is largely triggered at
puberty, and hypermethylation has been found in post-mortem brains of schizophrenic and bipolar patients.
Methods: In this study, we assessed RELN gene methylation status in post-mortem temporocortical tissue samples
(BA41/42 or 22) of six pairs of post-puberal individuals with ASD and typically developing subjects, matched for sex
(male:female, M:F = 5:1), age, and post-mortem interval.
Results: ASD patients display a significantly higher number of methylated CpG islands and heavier methylation in
the 5′ region of the RELN gene promoter, spanning from −458 to −223 bp, whereas controls have more methylated
CpG positions and greater extent of methylation at the 3′ promoter region, spanning from −222 to +1 bp. The
most upstream promoter region (−458 to −364 bp) is methylated only in ASD brains, while the most downstream
region (−131 to +1 bp) is methylated exclusively in control brains. Within this general framework, three different
methylation patterns are discernible, each correlated with different extents of reduction in reelin gene expression
among ASD individuals compared to controls.
Conclusions: The methylation pattern is different in ASD and control post-mortem brains. ASD-specific CpG
positions, located in the most upstream gene promoter region, may exert a functional role potentially conferring
ASD risk by blunting RELN gene expression.
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Background
Autism spectrum disorder (ASD) represents a heteroge-
neous collection of neurodevelopmental conditions charac-
terized by social and communication deficits, accompanied
by stereotypic and rigid patterns of behaviors, restricted
interests, and unusual sensory processing with onset in
early childhood [1]. Neuroanatomical and neuroimag-
ing studies on brains of autistic patients have shown
abnormalities stemming from deranged neurodevelop-
mental processes physiologically occurring during the
first and second trimester of pregnancy [2, 3]. During
embryogenesis, neuronal and glial precursor cells mi-
grate out of proliferative zones to reach their final
destination, where they soon establish intercellular con-
nections. The reelin protein plays a pivotal role during
neurodevelopment by acting as a stop signal for migrat-
ing neurons in several districts of the central nervous
system (CNS), including the neocortex, the cerebellum,
and the hindbrain [4–6]. The critical role of reelin in
CNS formation has been elucidated by observing pro-
found migration and cytoarchitectonic alterations in
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reeler mice, a loss of function model due to a spontan-
eous heterozygous deletion of the reelin (RELN) gene
[7]. Although reelin was initially studied in the context
of CNS embryonic development, more recent reports
have focused on the role of reelin in the adult brain,
particularly in memory processes and in higher cogni-
tive functions [5, 6]. Post-natally, reelin is expressed at
high levels primarily in the GABAergic interneurons of
the cerebral cortex, hippocampus, and olfactory bulb;
perhaps even more relevant to ASD, synaptic strength
and plasticity are enhanced by reelin signaling upon
binding to apoER2 and VLDLR receptors and subsequent
activation of NMDA and AMPA receptors [6, 8–10]. In
addition, it exerts a proteolytic activity on extracellular
matrix proteins, which is inhibited by organophosphates
[11]. Reelin signaling is also required for the development
of dendritic spines, which are crucial for signal transmis-
sion between neurons. Abnormal shape and reduced
numbers of dendritic spines have been found in the reeler
mouse and in some subjects affected by autistic disorder,
fragile X syndrome, and Rett syndrome [12, 13]. Finally, a
significant reduction of dopamine D2 and serotonin 5-
HT2A receptors was also reported in the frontal cortex of
the reeler mouse as well as in schizophrenic patients
[14]. In summary, reelin occupies a pivotal position in
the CNS, exerting either directly or indirectly a pro-
found influence on brain structure and function
through lifetime. The RELN gene contains at least two
alternative isoforms, one with an alternative polyadeny-
lated site and another one with a 6-bp-long microexon
[15, 16]. These isoforms are conserved across species
and may affect RELN gene expression being located at
the 3′ end.
This prominent physiological role immediately links
abnormal reelin expression to many neurodevelopmental
and psychiatric disorders, including ASD, schizophrenia,
bipolar disorder, major depression, and Alzheimer’s dis-
ease [17]. Homozygous RELN gene mutations are known
to produce in humans a rare recessive disease, the
Norman-Roberts syndrome, characterized by lissence-
phaly and cerebellar hypoplasia, with severe mental re-
tardation, abnormal neuromuscular connectivity, and
congenital lymphoedema [18]. Less disruptive genetic
variation has been found to confer autism risk. Common
RELN gene polymorphisms yielding lower reelin gene
expression both in vitro and in vivo have been found sig-
nificantly associated with autism in many, though not
all, studies [19–21]. Accordingly, post-mortem brain
studies have documented reductions in RELN gene ex-
pression both in the cerebral and cerebellar cortices of
ASD individuals compared to controls [22]. Similar re-
ductions have been found measuring reelin plasma levels
in vivo [23, 24]. Gene-gene interactions, especially
among genes involved in reelin pathway, as well as gene-
environment interactions involving various agents and
conditions known to enhance autism risk, such as pre-
natal immune activation, appear likely [25–29].
In addition to genetic variation, epigenetic control of
RELN gene expression has also been called into play,
initially by studies focused on schizophrenia [30]. The
importance of epigenetics in regulating RELN gene ex-
pression is also supported by our previous results, doc-
umenting prominent increases in RELN gene promoter
methylation in post-mortem temporocortical specimens
of post-puberal compared to pre-puberal typically de-
veloping individuals [31]. In particular, post-puberal
subjects displayed elevated methylation, especially at
CpG positions located between −222 and +1 bp, com-
pared to pre-puberal subjects who displayed little or no
methylation at all (Additional file 1: Figure S1) [31].
Abnormal methylation patterns at the RELN gene pro-
moter have been described in post-mortem brains of
schizophrenic and bipolar disorder patients [30, 32, 33].
In addition to the RELN gene, other important neuro-
developmental genes, such as UBE3A, GABA receptor
genes, and their regulator MeCP2, have also been found
epigenetically dysregulated in post-mortem ASD brains
[34]. Hence, epigenetic control could play functional
roles perhaps even more sizable and widespread than
the influence exerted by single functional genetic vari-
ants in conferring vulnerability to complex behavioral
disorders, such as schizophrenia and autism, or in
shaping their clinical course, especially after puberty.
To explore this hypothesis, we have mapped and
quantified RELN gene promoter methylation assessing
in parallel messenger RNA (mRNA) expression levels
in the post-mortem temporocortical gray matter
(Brodmann area 41/42 or 22) of six post-puberal ASD




Frozen post-mortem brain tissues dissected from the su-
perior temporal gyrus (BA 41/42 or 22, depending on
tissue availability) of six post-puberal ASD-control
pairs (Table 1) and three ASD pre-puberal subjects
were obtained from the NICHD Brain and Tissue Bank
for Developmental Disorders at the University of Maryland
and the Harvard Brain Tissue Resource Center, through
the Autism Brain Net (www.autismbrainnet.org). This neo-
cortical region was chosen because it plays a crucial role in
social cognition and hosts well-documented abnormalities
in ASD [35]. Largely overlapping post-mortem brain sam-
ples have been the object of several previous reports
from our group [31, 36–39]. Patients and controls were
matched by sex (male:female, M:F = 5:1), age (±2 years)
and PMI (Table 1).
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Table 1 Brain tissue information for ASD patients and controls
Pair no. Case no.a BA Diagnosis Age (years)b Sex PMI (h)c Cause of death Intellectual
disability
Epilepsy Other features Drug therapies at time
of deathd
1 AN11989 (B6677) 41/42 Autism 20 M 16 Cardiac arrest Yes Yes – Heart medication, Zoloft,
clomipramine
2 AN08792 (B5173) 41/42 Autism 30 M 20 Gastrointestinal
hemorrhage
Yes Yes Large ear lobes Dilantin, Depakote, Tranxene bid,
cisapride, clorazepate, folic acid,
oxcarbazepine
3 AN00764 (B5144) 22 Autism 20 M 23.7 Trauma Yes No – None
4 AN17138 (B6294) 41/42 Autism 16 M Unknown Seizure Unknown Yes Inherited 15q duplication Topamax, Depakote, Allegra,
Claritin, NuThera multivitamin




Abilify, flax seed oil, omega-3,
multivitamin
6 AN01570 (B6184) 41/42 Autism 18 F 6.75 Seizure Unknown Yes Focal slowing in the left
parieto-occipital area
None
1 AN10833 (B5718) 41/42 Control 22 M 21.5 Unknown No No – None
2 B4211 41/42 Control 30 M 23 Cardiac arrhythmia No No – None
3 AN04432 (B3829) 22 Control 22 M 12 Central hepatic
laceration
No No – None
4 AN17425 (B6207) 22 Control 16 M 26 Ischemic heart attack No No – None
5 AN14368 (B6221) 41/42 Control 22 M 24 Unknown No No – None
6 UMB1541 22 Control 20 F 19 Head injuries No No – None
BA Brodmann area, PMI post-mortem interval
aAutism Tissue Program identifier
bMean age (±SD) for the autism group = 21.0±2.9, for controls = 22.0±1.8; t = −0.368, df = 10, p = 0.721
cMean PMI (±SD) for the autism group = 18.2+3.2, for controls = 20.9±2.0, t = −0.707, df = 9, p = 0.497














DNA was recovered by phenol/chloroform extraction
and ethanol precipitation, following brain tissue diges-
tion with proteinase K at 55 °C overnight. One micro-
gram of genomic DNA dissolved in 20 μl of distilled water
was denatured in 0.3 M NaOH for 15 min at 37 °C and
treated with a freshly prepared urea-sodium bisulfite solu-
tion (5.36 and 3.44 M, respectively, at pH 5.0), in the pres-
ence of 0.5 mM hydroquinone. Samples were mixed and
incubated for 6 cycles, each encompassing 15 min at
55 °C and 30 s at 95 °C, followed by 14 h at 55 °C.
DNA was then purified using a desalting column (Wizard
Clean Up, Promega), according to the manufacturer’s
protocol. Desulfonation and ethanol precipitation were
then carried out, as described in [40]. To minimize inter-
individual variability due to experimental conditions, all
samples, positive control and negative control, were proc-
essed simultaneously. An in vitro methylated DNA, ob-
tained using the CpG methyltransferase M.SssI (New
England Biolabs, Ipswich, MA), was used as a positive
control for bisulfate conversion. As a negative control,
tissue from UMB1185 was used. This tissue derives
from a control pre-puberal subject, which was previ-
ously shown to be entirely unmethylated, and thus, it
demonstrates a complete C-to-T conversion during bi-
sulfite treatment [31].
Post-mortem confirmation of consent was obtained
from next of kin for use of donor brain tissue and publica-
tion of individual details presented in this manuscript.
Consent forms are held by the NICHD Brain and Tissue
Bank for Developmental Disorders at the University of
Maryland and the Harvard Brain Tissue Resource Center.
Reelin promoter amplification by nested PCR, DNA
cloning, and sequencing
Bisulfite-converted genomic DNA was amplified by
nested PCR. The RELN gene region spanning from −516
to +344 bp (+1 is the transcription start site; Genbank
acc. n. AC002067) was divided into three amplicons, as
follows: amplicon 1 outer primers, −516 (forward), 5′-
GGAAAAATAGGGTATATTG-3′, and +115 (reverse), 5′-
CACATTCAATTTTAAAAAC-3′; inner primers, −495
(forward), 5′-GTTAAAGGGGTTGGTTTTT-3′, and −132
(reverse), 5′-ACCAAACCTAAAAAAAC-3′; amplicon 2
outer primers, −148 (forward), 5′-GTTTTTTTAGGTTT
GGT-3′, and +200 (reverse), 5′-CTAAAAAAAAAATC
TACC-3′; nesting reverse primer, +115, 5′-CACATTC
AATTTTAAAAAC-3′; and amplicon 3 outer primers, −42
(forward), 5′-GGTTTAAAGTAATTTTGGGAGT-3′,
and +344 (reverse), CAATATACAAAAAAATAAACA
CC-3′; nesting forward primer, +97, 5′-GTTTTTAAA
ATTGAATGAG-3′. First- and second-round PCRs
were performed in a total volume of 25 μl including
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
0.8 mM dNTPs, 1.5 U of TaKaRa Taq™ Hot Start Ver-
sion (TaKaRa, Shiga, Japan), and 0.4 μM of each primer
(Invitrogen, Carlsbad, CA). Approximately 30 ng of
bisulfite-converted genomic DNA was used as a tem-
plate for the first PCR; 4 μl of a 1:20 dilution of the first
PCR product was used as a template for the second
PCR. PCR cycling conditions for the first two ampli-
cons were 95 °C for 5 min; 35 cycles at 95 °C for 30 s,
43 °C for 30 s, and 72 °C for 30 s; and 72 °C for 10 min.
PCR conditions for the third amplicon differ only in the
annealing temperature of the first- and the second-round
PCRs which were 53 and 50 °C, respectively. PCR prod-
ucts were analyzed by electrophoresis on a 1.5 % agarose
gel, stained with ethidium bromide and visualized under
UV light. PCR products were then cloned into the
pCR2.1-TOPO cloning vector (Invitrogen, Carlsbad, CA),
using the TOPO TA reagents according to the manu-
facturer’s protocol. DNA sequencing was performed on
17–21 clones per each individual, using a CEQ8000
DNA sequencer (Beckman-Coulter, Fullerton, CA).
Fragment analysis for GGC genotyping
The GGC repeat was PCR amplified using primers
SGR1 5′-CGGCGTCTCCAAAACTGAAT-3′ and with
the FAM-labeled SGR2 5′-AACAGCGCTAGGAGGA
AAGT-3′. PCR was performed in a total volume of 20 μl
using 100 ng of genomic DNA, 10 mM Tris-HCl (pH
8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs
(dATP, dTTP, and dCTP), 0.15 mM dGTP and 0.05 mM
deaza-dGTP (Roche Diagnostics GmbH, Mannheim,
Germany), Taq Gold polymerase (Applied Biosystems,
Foster City, CA, USA), 0.4 μM each primer (Invitrogen,
Carlsbad, CA), and 10 % DMSO. Each cycle consists in a
denaturation step at 94 °C for 1 min, an annealing step
at 65 °C for 1 min, and a polymerization step at 72 °C
for 2 min. After PCR, DNA typing was performed by ca-
pillary electrophoresis using the ABI 3500 XL Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA).
The LIZ-labeled ladder (GeneScan 500 LIZ) was used
for sizing determinations of the amplified fragments,
and the number of fragment repeats was based by com-
parison with the allelic ladder.
Real-time PCR
Total RNA was extracted from temporocortical brain
tissue immediately adjacent to the tissue specimen used
for genomic DNA extraction, using the TRIzol method
(Invitrogen, Carlsbad, CA). RNA quality was checked
using a Bioanalyzer (Agilent, Santa Clara, CA). RNA
(1 μg) was reverse transcribed using the QuantiTect
Reverse Trascription kit (Qiagen, Hilden, Germany).
RELN complementary DNA (cDNA) levels were mea-
sured using an ABI PRISM 7900HT Real-Time PCR sys-
tem using a standard amplification protocol. Total
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RELN cDNA was measured using a standard SYBR
Green-based comparative protocol (2−ΔΔCt) [41]. We
also measured the proportion of the alternative polyade-
nylated transcript (polyA) and of the alternatively spliced
microexon applying the same delta subtractive Ct meth-
odology described by Ovadia and Shifman [16]. The hu-
man CHL1 gene was measured in parallel and used as a
normalizer. cDNA dilutions (1:10) were used to quantify
all transcripts. All samples were reverse transcribed in
duplicate, and cDNA was run in quadruplicate to allow
assessment of sample homogeneity and technical vari-
ability. Primer sequences were the same as used by Ova-
dia and Shifman [16] with the exception of the primer
set for the microexon for which the following new
primers were designed: 5′-GTGGAGGTCGTCCTAG-
TAAG-3′ forward primer and 5′-TTGATTCTTCATGG
GTATCGCC-3′ reverse primer.
The specificity of the PCR product was checked by
running a melting curve at the end of each experiment.
The efficiency of the PCR amplification was assessed by
serial dilutions for each primer set (>0.95 for all sets).
Little variability was observed among controls and ASD
samples (Additional file 2: Figure S2).
In silico analysis
The biostatistical softwares Alibaba 2, Match, and P-
Match were used to predict the presence of putative tran-
scription factor binding sites in the RELN gene promoter
(http://www.gene-regulation.com/pub/programs.html).
Statistical analysis
Methylation was evaluated applying two different indi-
ces: (a) “percent of methylation” index (number of meth-
ylated clones/total number of clones at each CpG
position), to quantify the extent of methylation at each
CpG position, and (b) “extent of methylation” index
(number of methylated CpG positions in a given individ-
ual/total number of CpG positions along the reelin pro-
moter) to study the overall distribution of methylated
CpGs along the RELN gene promoter. These two indices
essentially reflect the intensity and the extension of
methylation along the RELN gene promoter, respectively.
A position was given methylated when it was found
methylated in at least two clones from the same indi-
vidual. Considering the small sample size of available
brain specimens, non-parametric tests Wilcoxon test
for paired data and two-tail probability thresholds were
employed to compare RELN gene promoter methyla-
tion and expression in ASD vs typically developing con-
trols. Correlation between RELN gene expression levels
(expressed as ΔCt) and methylation indices was
assessed applying the Spearman correlation index. Post-
mortem confirmation of consent was obtained from
next of kin for use of donor brain tissue and
publication of individual details presented in this
manuscript. Consent forms are held by the NICHD
Brain and Tissue Bank for Developmental Disorders at
the University of Maryland and the Harvard Brain Tis-
sue Resource Center. This study was approved by the
I.R.B. of University Campus Bio-Medico (23.06), and it
is in compliance with the Helsinki Declaration.
Results
Differential methylation at the RELN gene promoter
between ASD and control brains
ASD and control brains collectively display methylation
at 24 different CpG positions distributed along the RELN
gene promoter between −458 and −43 bp (Figs. 1 and 2).
Percentage of methylation and number of methylated
CpG positions display broad interindividual variability.
The mean percentage of methylation at each CpG pos-
ition and the mean number of methylated CpGs along
the entire RELN gene promoter do not differ signifi-
cantly between ASD and control brains (two-tail p = 0.34
and p = 0.46, respectively) (Table 2). However, the distri-
bution of methylated CpG positions across the RELN
gene promoter is different between ASD and control
brains. As shown in Fig. 2, ASD brains carry signifi-
cantly more numerous and more heavily methylated
CpG positions in the 5′ portion of the RELN gene pro-
moter, spanning from −458 to −223 bp, reaching two-
tail p values of 0.04 for both indices (Table 2). On the
contrary, the 3′ promoter region, spanning from −222
to +1 bp, displays a methylation pattern exclusively re-
stricted to controls (Fig. 2), despite not reaching a sig-
nificant two-tail p value for both methylation indices
due to small sample size and slightly lower methylation
intensity (Table 2).
CpG positions uniquely methylated in ASD brains are
all located in the 5′ promoter region and include −458,
−411, −402, −364, −324, −309, −303, −268, and −223
(Figs. 2 and 3). Interestingly, CpG position at −458 is
methylated in three ASD subjects with 20 % mean
extent of methylation (Fig. 2) and is within the puta-
tive DNA binding site of the transcription factor
ELK-1. Conversely, other CpG positions, mainly lo-
cated in the 3′ promoter region, are methylated only
in controls, including −346, −340, −289, −131, −124,
−119, −111, −108, −105, −102, −98, −85, and −43,
(Figs. 2 and 3). CpG position at −131 is methylated
in three out of six control brains with 12 % mean ex-
tent of methylation (Fig. 2).
No or very little methylation at the RELN gene pro-
moter was found in ASD pre-puberal subjects demon-
strating that methylation is triggered at puberty
(Additional file 1: Figure S1). Similarly, one post-
puberal ASD individual with a pituitary dysfunction
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(AN00493) displayed a pre-puberal-like methylation
pattern characterized by only one methylated CpG pos-
ition (33 % methylation at −289 CpG only) and was
thus excluded from the study (data not shown).
RELN gene expression in post-mortem ASD brains and
relationship with distinct methylation patterns
Autistic brains display a significant reduction in RELN
total mRNA levels compared to their matched controls
Fig. 1 Position of methylated CpGs and percent of methylation at the RELN gene promoter in six post-puberal ASD brains (black bars) and their
matched controls (white bars)
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(two-tail p < 0.05) (Fig. 4a). Instead, no significant differ-
ence in the proportion of the RELN alternative polyA
and microexon isoforms was detected (Fig. 4b, c). The
relationship between gene expression and promoter
methylation is not strictly quantitative and linear. In fact,
no overall correlation between total RELN mRNA levels,
expressed as ΔCt, and the two methylation indices was
found (p > 0.05 for the Spearman correlation index) re-
gardless of diagnostic status. However, three general
methylation patterns appear differentially associated with
expression levels, based on the ratio between the num-
ber of methylated CpGs in each ASD and control pair
(compare Fig. 1 with Fig. 4b): (a) pairs n.2, n.3, and n.6
display the heaviest methylated CpGs in ASD compared
to controls, corresponding to the most decreased ASD/
CON expression ratios, as low as <0.3; (b) pairs n.1 and
n.5 have relatively methylated CpGs in ASD compared
to little or no methylation in controls, corresponding to
even or modestly decreased ASD/CON expression ra-
tios, between 0.6 and 0.8; and (c) pair n.4 shows more
and heavier methylated CpGs in controls compared to
ASD corresponding to a 1.1-fold change. Within this
framework, the extent of CpG methylation seemingly ex-
erts greater influence on gene expression than the over-
all number of methylated CpG sites (Figs. 1 and 4).
The RELN GGC triplet repeat does not explain reduced
mRNA levels
The presence of “long” GGC repeat alleles does not sig-
nificantly contribute to these differences in RELN
methylation status, as all individuals carry the common
Fig. 2 a Mean percentage of methylation at each methylated CpG position (top) and presence of methylation in the six ASD (red) and six control
(green) temporocortical specimens from post-puberal individuals (pairs n.1–6 in Table 1). b Cumulative percentage of methylation in the three
regions of the RELN gene promoter. Region 1, from −458 to −324; region 2, from −315 to −223; and region 3, from −131 to −43
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8 and 10 repeat alleles, except for the control subject of
pair number 3 (AN04432: genotype 10/12).
Discussion
The present results provide for the first time a map of
RELN gene promoter methylation in temporocortical tis-
sue samples from post-puberal ASD and matched con-
trol brains, demonstrating differences in the distribution
of methylated CpGs, while confirming reductions in
RELN mRNA levels in ASD brains compared to con-
trols. Our study was restricted to post-mortem brains
from post-puberal individuals, since we previously dem-
onstrated a substantial lack of methylation at the RELN
gene promoter before puberty in control brains [31]. We
found the same lack of methylation in ASD pre-puberal
brains in this study (Additional file 1: Figure S1). In line
with previous data supporting genome-wide epigenetic
and transcriptomic abnormalities in ASD brains [37, 42],
Fig. 3 Methylation status at the RELN gene promoter in case-control pairs n.1–6. CpGs uniquely methylated in post-puberal ASD or control brains
are highlighted in red and in green, respectively, while CpGs methylated in both are shown in light blue. The trascription start site and translation
start site are boxed in gray. Response elements with high affinity (less than three mismatches with respect to the consensus sequence) are boxed
in black
Table 2 Summary statistics of RELN gene promoter methylation indices
Promoter region ASD Controls p value
Mean percent of methylationa 5′ region (−458 to −223 bp) 29.55 ± 13.09 5.70 ± 2.90 0.04*
3′ region (−222 to +1 bp) 0 10.83 ± 5.04 0.10
Total region (−458 to +1 bp) 29.55 ± 13.09 16.00 ± 4.21 0.34
Mean extent of methylationb 5′ region (−458 to −223 bp) 0.16 ± 0.01 0.04 ± 0.01 0.04*
3′ region (−222 to +1 bp) 0 0.21 ± 0.10 0.10
Total region (−458 to +1 bp) 0.09 ± 0.01 0.11 ± 0.04 0.46
Data are expressed as means ± standard error of the mean. Two-tail p values were obtained using non-parametric Wilcoxon tests
*p < 0.05
a(mean number of methylated clones at each CpG position/total number of clones) × 100
b(mean number of methylated CpG positions in a region/the total number of methylated CpG positions in that region) × 100
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our results zoom into the RELN gene which is relevant,
on the one hand, to physiological neurodevelopment
and post-natal synaptic management, as well as, on the
other hand, to the pathological neurodevelopment
underlying several neurodevelopmental disorders, in-
cluding ASD [17]. Collectively, our results indicate that
(a) decreased total RELN gene expression is a wide-
spread phenomenon in ASD brains and (b) it seemingly
stems from an epigenetic dysregulation resulting in
heavier and broader methylation of promoter regions lo-
cated further upstream those typically methylated in
control brains. This epigenetic dysregulation appears in-
dependent of autism-associated rare genetic variants,
which have an extremely low incidence, and of known
functional common variants, including the previously
described GGC repeat [19–21]. The proportions of the
alternative polyA and microexon RELN mRNA isoforms
are in line with previously reported data [15, 16], being
about 15 % and 80–92 % of total RELN mRNA, respect-
ively (Fig. 4b, c).
Several lines of evidence demonstrate that the RELN
gene promoter is epigenetically controlled, including (a)
a switch in the RELN gene expression pattern from em-
bryogenesis to post-natal life [43], (b) a significant dif-
ference in RELN gene promoter methylation and
expression levels between pre-puberal and post-puberal
brains in typically developing subjects [31], (c) in-
creased RELN promoter methylation in post-mortem
brains of bipolar disorder and schizophrenic patients
[30, 32, 33], and (d) increased RELN promoter
methylation and downregulation of its expression in rat
pups exposed to pre-natal restraint stress or post-natal
maternal deprivation [44, 45]. Histone modifications
not requiring DNA methylation could be involved in
the modulation of gene expression prior to puberty,
whereas methylation arises and plays a prominent role
in post-puberal brains [31]. However, the present study
demonstrates that methylation patterns differ between
ASD and control brains. Methylated CpG positions are
restricted to the −458- to −223-bp promoter region in
post-mortem autistic brains, whereas methylation spans
a broader −346- to −43-bp region in matched controls
(Fig. 2). ASD and control methylation overlaps between
−346 and −231 bp, albeit largely at different CpG sites
(Figs. 2 and 3). Two promoter regions display no over-
lap, namely the upstream −458- to −364-bp region,
which is methylated only in ASD brains, and the down-
stream −131- to −43-bp region, which is methylated ex-
clusively in control brains (Figs. 2 and 3). This difference
in the methylation status of the RELN promoter may have
important functional consequences on reelin gene expres-
sion. For example, CpG position at −458 is uniquely
methylated in three out of six autistic patients and local-
izes inside a putative ELK-1 transcription factor binding
site. This factor binds to specific DNA sites containing a
central GGA trinucleotide motif [46] and has been found
associated with the mitochondria transition pore complex
(PTP), a structure involved in both apoptotic and necrotic
cell death [47]. In particular, overexpression of ELK-1 in
primary neurons decreased cell viability, whereas its
Fig. 4 a RELN gene expression in six ASD post-mortem brains relative to their matched control and mean ASD/control fold difference; the
hyphenated line corresponds to no case-control difference in mRNA levels. *two-tail p < 0.05. b Mean proportion of alterative polyadenylation and
c microexon RELN isoforms for controls (green) and for ASD (red); error bars correspond to the standard error of the mean
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knockdown increased cell viability [47]. Hence, the bind-
ing of ELK-1 to its response element might be decreased
or prevented by specific methylation of this CpG residue,
suggesting a putative functional role for this specific pos-
ition. Alternatively, the chromatin conformation associ-
ated with methylation of the −458- to −364-bp region
could interfere with ELK-1 binding, even in the absence of
methylation specifically at −458 bp. Further work will be
necessary to explore these hypotheses. Sex-specific differ-
ences in RELN expression have been found in several ani-
mal model studies. Studies on rats have demonstrated that
female progesterone upregulates reelin expression at the
periphery [48] whereas the reeler male mouse has a sig-
nificant higher loss of Purkinje cells in the cerebellum
compared to females [49]. In addition, some RELN gene
SNPs have been associated with schizophrenia and bipolar
disorder only in women [50, 51]. We did not notice any
sex difference in RELN expression and/or methylation pat-
tern in our sample. However, our sample is very small and
includes only one female pair.
In addition to differential methylation, most brains of
post-puberal autistic subjects display a significant down-
regulation of reelin gene expression compared to
matched controls (Fig. 4b), in line with previous reports
[22–24]. Furthermore, we observe three possibly distinct
methylation patterns each related to differential degrees
of expression blunting in ASD compared to control
brains. The relationship between promoter methylation
and gene expression levels observed in this study should
be viewed as preliminary, but nonetheless, it points to-
ward a functional role of distinct RELN gene promoter
methylation patterns in differentially modulating RELN
mRNA expression. Considering the functional relevance
of the reelin protein in synaptic management, increased
methylation at the 5′ promoter region and downregula-
tion of RELN gene expression at puberty could indeed
contribute to the worsening of some phenotypic traits
observed clinically in many autistic subjects at the onset
of adolescence [52]. Well-known clinical features often
aggravating or arising soon after puberty include epi-
lepsy and abnormalities of movement, speech, and be-
havior [52]. In addition to hormonal changes occurring
at puberty, also pre-natal and/or early post-natal stress
may play a role, since newborn rats whose mothers were
exposed to pre-natal restraint stress show increased
methylation at the RELN gene promoter and, as adults,
higher locomotory activity, as well as learning and mem-
ory deficits [45]. Similarly, rat pups removed from their
mothers during post-natal days 2–15 for 3 h/day show
reduced hippocampal RELN gene expression and hyper-
methylation of the RELN gene promoter, accompanied
by behavioral deficits in auditory startle and grasping re-
flex, as well as greatly enhanced responses to the hot
plate [44]. Collectively, these and the present results
suggest that the epigenetic regulation of the RELN gene
promoter by hormonal and environmental factors may
also confer significant vulnerability toward a variety of
behavioral disorders, including autism, or influence their
developmental trajectory, as does genetic variation at
this locus.
The epigenetic regulation of the RELN gene promoter
is very complex and involves several response elements,
bound by specific transcription factors. In general, down-
regulation of RELN gene expression in the brain of schizo-
phrenic and bipolar patients has been linked to the
overexpression of DNA methyltransferase 1 (DNMT1)
and ten-eleven translocase methylcytosine dioxygenase 1
(TET1) [53]. Furthermore, the neocortex of schizophrenic
and bipolar patients displays an increase in DNMT1 bind-
ing to the RELN gene promoter [54]. This increased bind-
ing of DNMT1 positively correlates with increased
expression of DNMT1 and with promoter binding of me-
thyl binding domain 2 (MBD2) but not necessarily with
enrichment in promoter methylation. This last observa-
tion suggests that cytosine methylation may not represent
the only mechanism by which DNMT1 modulates gene
expression. Indeed, DNMT1 not only binds to methyl-
ated CpGs through its methyl binding domain (MBD)
but also binds to unmethylated CpGs through its
CXXC zinc finger domain [55]. In addition to DNMT1,
also MeCP2 binds to the RELN gene promoter, modu-
lating its expression. Specifically, an enrichment of 5-
hydroxylmethylcytosine relative to 5-methylcytosine
seems to mediate an increased binding of MeCP2 to
the RELN gene promoter in the cerebellar cortex of
ASD individuals [56]. Gene expression is thus the result
of complex interactions exerted by different biological
processes, including DNA methylation/demethylation/
hydroxylmethylation, trans-acting chromatin-associated
proteins, and non-coding RNAs [17, 57].
The small sample size assessed here, typical of most
post-mortem studies, requires caution in interpreting
our results as necessarily valid for all patients in such a
highly heterogeneous disorder. Independent replications
in additional human post-mortem brain samples, investi-
gations employing rodent models, and functional in vitro
studies will be needed to clarify the involvement of spe-
cific CpG dinucleotides in controlling RELN gene ex-
pression and their potential role in ASD.
Conclusions
Methylation patterns in post-mortem neocortical tissue
of post-puberal ASD and control individuals are differ-
ent, with an upstream promoter region methylated spe-
cifically in ASD brains, while a downstream region is
methylated only in controls. The potential relationship
between methylation patterns and RELN gene expression
observed here is intriguing and deserves further
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investigation, as do the underlying transcriptional con-
trol mechanisms which will now be addressed in follow-
up studies. RELN gene expression in peripheral lympho-
cytes has been reported to be very low [58]; however,
should methylation patterns at the RELN gene promoter
display some parallels between brain and leukocytes, it
may be possible to assess the clinical correlates of abnor-
mal methylation in autistic individuals at puberty and
during adolescence. Finally, it is unclear whether DNA
methylation changes are causally inferred, given ASD
stress, or represent a core element of the etiology itself.
The present results confirm the potential contribution
of epigenetics to the definition of biomarker panels for
neurodevelopmental disorders [59], although the tissue
specificity of methylation marks represents an add-
itional challenge as compared to genetic and biochem-
ical biomarkers.
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